Dr. Cohen Discusses CAR T-Cell Therapy in MCL

Video

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the use of CAR T-cell therapy in patients with mantle cell lymphoma.

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with mantle cell lymphoma (MCL).

CAR T-cell therapy is being explored as a treatment option for patients with relapsed/refractory MCL. Currently, the phase II ZUMA-2 trial is evaluating the use of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed/refractory MCL who no longer respond to treatment. Cohen says that at Winship Cancer Institute, patients with MCL enrolled on this trial have done very well, which suggests that there is a place for this treatment approach in the MCL landscape.

Like other lymphoma subtypes, the challenge is finding where CAR T-cell therapy fits into the treatment algorithm, Cohen says. In aggressive lymphomas, it is easier to determine this, he explains, because there are not many novel therapies available to offer. For those patients who have progressed after an autologous stem cell transplant or who are ineligible for transplant, CAR T-cell therapy can be a potential treatment option. However, he adds that there are several drugs available and in development for MCL that do not require the intensive treatment that CAR T-cell therapy does, says Cohen, making the placement for this therapy even more of a challenge.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.